A pill version of the GLP-1 weight-loss drug Wegovy is expected to debut in the U.S. in early January. But how will the pills ...

Quick Read Novo Nordisk (NVO) received FDA approval for the first oral Wegovy pill. The once-daily tablet delivered 16.6% ...

A daily weight-loss pill will soon be available in the US, after the regulator gave approval to Danish drug company Novo ...

The US food and drug administration (FDA) has approved a daily pill version of Novo Nordisk’s weight-loss drug Wegovy, ...

LONDON, Dec 23 () - Novo Nordisk's newly approved weight-loss pill version of Wegovy will be a test case for the fast-growing ...

The FDA approves the first daily oral GLP-1 weight-loss medication. The company plans to have the pill in pharmacies next ...

The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk's weight-loss drug Wegovy, ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

If the enhanced credits currently available to Affordable Care Act (ACA) Marketplace enrollees are allowed to expire for 2026 ...

Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...